Irinotecan Solid Oral Dosage Form with Enteric Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral formulations of Irinotecan exhibit low and variable bioavailability, limiting their effectiveness in treating cancers such as metastatic colorectal and breast cancer, due to challenges in solubility and absorption.
Innovation Solution
A solid oral composition of Irinotecan solubilized in a mixture with a non-ionic surfactant and enteric coating, enhancing bioavailability and reducing absorption variability, achieved by using a combination of a vehicle and a non-ionic surfactant to create a stable and effective pharmaceutical form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oral formulations of Irinotecan are used, then the formulation is simple and easy to manufacture, but the oral bioavailability is low and variable
Solution Approach 1:
The patent employs a composite formulation system comprising Irinotecan combined with specific excipients including polyethylene glycol (PEG), surfactants (such as polysorbate 80 or poloxamer 188), and enteric coating materials. This composite approach enhances solubility and absorption consistency, achieving reliable oral bioavailability while managing formulation complexity through systematic selection of compatible materials.
Solution Approach 2:
The patent utilizes enteric coating to alter the dissolution parameters of Irinotecan by controlling pH-dependent release. The coating prevents premature degradation in the acidic stomach environment and facilitates controlled release in the alkaline intestinal environment, thereby improving bioavailability reliability without requiring complex formulation systems.
2Ease of operation
If intravenous administration is used, then the bioavailability is high and consistent, but the patient requires frequent clinic visits and infusion time
Solution Approach 1:
The patent develops an oral formulation that acts as an intermediary between the patient and the chemotherapy agent. By formulating Irinotecan with appropriate excipients and enteric coating, the oral route becomes a viable alternative to intravenous administration, enabling home-based treatment while maintaining consistent bioavailability through controlled release mechanisms.
Solution Approach 2:
The patent leverages phase transition properties of the enteric coating to control drug release. The coating remains intact in the acidic stomach phase but dissolves in the alkaline intestinal phase, facilitating controlled release of Irinotecan. This phase-dependent release mechanism ensures consistent bioavailability comparable to intravenous administration while providing administration convenience.
3Reliability
If frequent dosing is implemented, then the anti-tumor activity is improved, but the total treatment time and patient burden increase
Solution Approach 1:
The patent enables continuous anti-tumor action through frequent oral dosing. The enteric-coated formulation ensures consistent drug availability in the bloodstream, allowing patients to receive frequent small doses at home. This continuous administration maintains effective drug levels to suppress tumor growth while eliminating the need for lengthy infusion sessions, thereby improving anti-tumor activity without proportionally increasing patient burden.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described composition achieves high oral bioavailability and low variability in absorption, comparable to intravenous administration, improving treatment efficacy and reducing side effects, making it suitable for home treatment of cancers like metastatic colorectal and breast cancer.
Implementation Method 1
Irinotecan is solubilized in a mixture comprising a vehicle and a non-ionic surfactant
Implementation Method 2
the composition is coated with an enteric coating
Data Source
AI summary
Provided is a composition, in particular a solid pharmaceutical composition comprising a compound having the formula Ias a free base or a salt thereof, and a mixture comprising a vehicle and a non-ionic surfactant in an amount sufficient to achieve solubilization of compound (I), wherein typically the composition is coated with an enteric coating and its use in the treatment of cancer.